Figure 1. C-reactive protein and survival in patients with myocarditis. Kaplan–Meier survival curves in the entire studied cohort (A) and according to CRP levels (B).

Figure 2. Variable importance plot according to the random forest algorithm. AECA, anti-endothelial cell auto-antibodies; AHA, anti-heart auto-antibodies; AIDA, anti-intercalated disk auto-antibodies; ANA, anti-nuclear auto-antibodies; CRP, C reactive protein; OS, organ specific.

Figure 2. Variable importance plot according to the random forest algorithm. AECA, anti-endothelial cell auto-antibodies; AHA, anti-heart auto-antibodies; AIDA, anti-intercalated disk auto-antibodies; ANA, anti-nuclear auto-antibodies; CRP, C reactive protein; OS, organ specific.

Figure 3. Plot of the marginal effect of left ventricular ejection fraction (LVEF), anti-nuclear auto-antibodies (ANA) and biopsy proven status on 3-year predicted survival probability.

Table 1. Patients’ characteristics.

Table 1. Patients’ characteristics.

All
n = 409Abnormal
CRP Levels
n = 288Normal
CRP Levels
n = 121Missing
Datap-ValueAge, years37 ± 1536 ± 1539 ± 16-0.23Sex, male301 (74)224 (78)77 (64)-0.003EMB-proven myocarditis129 (32)74 (26)55 (45)-<0.001Clinically suspected myocarditis280 (68)214 (76)66 (24)-<0.001Hypertension61 (15)39 (14)22 (18)-0.23Diabetes11 (3)7 (2)4 (3)-0.62Immune-mediated diseases56 (14)37 (13)19 (16)20.46Acute viral infection in the preceding 6 months191 (47)158 (55)33 (28)3<0.001Symptoms duration, months0.5 (0.06–3)0.2 (0.03–1)3 (0.3–18)257<0.001Chest pain223 (55)172 (60)51 (42)-<0.001Palpitations41 (10)20 (7)21 (17)-0.002Syncope20 (5)8 (3)12 (10)-0.002Symptoms variation in the 12 months preceding diagnosis66 (16)39 (14)27 (22)-0.029Clinical presentation, infarct-like25 (6)19 (7)6 (5)-0.53Clinical presentation, heart failure68 (17)46 (16)22 (18)-0.58Clinical presentation, arrhythmias39 (10)12 (4)27 (22)-<0.001NYHA class II-IV61 (15)37 (12)24 (21)10.054LV heart failure at presentation69 (17)47 (16)22 (18)-0.65RV heart failure at presentation26 (6)18 (6)8 (7)-0.89Troponin I, ng/L4455 (438–13684)6140 (1148–15298)1150 (12–6030)-<0.001AHA positivity174 (52)112 (48)62 (61)750.025AIDA positivity116 (35)75 (32)41 (41)740.25AECA positivity3 (1)2 (1)1 (1)960.91ANA positivity37 (12)26 (11)11 (11)880.95LVEF Angio, %53 ± 1754 ± 1653 ± 18-0.87LVEDVi Echo, mL/m268 ± 2467 ± 2270 ± 28600.69LVEF Echo, %51 ± 1351 ± 1350 ± 14270.65RVEDA Echo, cm220.8 ± 4.720.7 ± 4.321.0 ± 5.72050.96RVFAC Echo, %42.1 ± 9.842.2 ± 10.441.9 ± 8.52190.73Mitral regurgitation Echo, moderate-severe34 (10)26 (10)8 (9)780.84LVEDVi CMR, mL/m288 (78–104)88 (79–102)90 (74–106)-0.83RVEDVi CMR, mL/m282 (74–94)84 (74–95)80 (70–91)-0.22LVEF CMR, %57 (52–62)57 (53–62)59 (51–62)-0.69RVEF CMR, %58 (54–63)58 (53–62)59 (55–65)-0.12Presence of myocardial edema on CMR190 (58)145 (61)50 (47)810.014Presence of myocardial LGE on CMR288 (88)210 (90)78 (84)830.17Lateral wall LGE37 (17)31 (20)6 (9)1900.028